Capital Planning LLC Increases Holdings in Stryker Co. (NYSE:SYK)

Capital Planning LLC increased its holdings in shares of Stryker Co. (NYSE:SYK) by 3.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 841 shares of the medical technology company’s stock after purchasing an additional 29 shares during the period. Capital Planning LLC’s holdings in Stryker were worth $304,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Empirical Asset Management LLC purchased a new stake in Stryker during the 4th quarter worth $18,488,000. Fermata Advisors LLC boosted its position in Stryker by 42.7% during the 4th quarter. Fermata Advisors LLC now owns 2,036 shares of the medical technology company’s stock worth $733,000 after purchasing an additional 609 shares during the period. JGP Wealth Management LLC lifted its holdings in Stryker by 0.4% in the 4th quarter. JGP Wealth Management LLC now owns 10,474 shares of the medical technology company’s stock worth $3,771,000 after buying an additional 37 shares in the last quarter. Ritholtz Wealth Management raised its stake in shares of Stryker by 3.5% in the 4th quarter. Ritholtz Wealth Management now owns 5,322 shares of the medical technology company’s stock valued at $1,916,000 after purchasing an additional 182 shares in the last quarter. Finally, Carnegie Investment Counsel raised its stake in shares of Stryker by 1.5% in the 4th quarter. Carnegie Investment Counsel now owns 114,184 shares of the medical technology company’s stock valued at $41,112,000 after purchasing an additional 1,731 shares in the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Stryker Price Performance

NYSE SYK opened at $381.32 on Friday. Stryker Co. has a 52 week low of $307.23 and a 52 week high of $398.20. The company has a current ratio of 1.91, a quick ratio of 1.22 and a debt-to-equity ratio of 0.66. The stock has a market cap of $145.36 billion, a price-to-earnings ratio of 40.87, a price-to-earnings-growth ratio of 2.51 and a beta of 0.95. The company has a 50-day moving average price of $375.12 and a two-hundred day moving average price of $358.32.

Stryker (NYSE:SYK) last posted its earnings results on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, topping the consensus estimate of $2.77 by $0.10. The firm had revenue of $5.49 billion during the quarter, compared to analysts’ expectations of $5.37 billion. Stryker had a net margin of 16.34% and a return on equity of 23.07%. Stryker’s quarterly revenue was up 11.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned $2.46 EPS. Analysts forecast that Stryker Co. will post 12.06 EPS for the current year.

Stryker Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Stockholders of record on Tuesday, December 31st will be issued a $0.84 dividend. The ex-dividend date is Tuesday, December 31st. This is a boost from Stryker’s previous quarterly dividend of $0.80. This represents a $3.36 annualized dividend and a dividend yield of 0.88%. Stryker’s dividend payout ratio (DPR) is 36.01%.

Analyst Ratings Changes

SYK has been the topic of a number of recent analyst reports. Needham & Company LLC restated a “buy” rating and issued a $442.00 target price on shares of Stryker in a research note on Tuesday, January 7th. Barclays upped their target price on shares of Stryker from $402.00 to $418.00 and gave the company an “overweight” rating in a research note on Thursday, October 31st. Royal Bank of Canada restated an “outperform” rating and issued a $425.00 target price on shares of Stryker in a research note on Tuesday, January 7th. UBS Group boosted their price objective on shares of Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Finally, Wells Fargo & Company boosted their price objective on shares of Stryker from $405.00 to $427.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company. According to data from MarketBeat.com, Stryker presently has a consensus rating of “Moderate Buy” and a consensus price target of $405.80.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the stock in a transaction that occurred on Thursday, November 7th. The shares were sold at an average price of $368.70, for a total value of $21,131,303.10. Following the completion of the transaction, the chief executive officer now directly owns 100,027 shares in the company, valued at $36,879,954.90. This trade represents a 36.43 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 5.50% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.